Does GERN pay a dividend?

The cached stock data on this page does not show a positive dividend yield for GERN. Dividend status can change, so verify the latest company filings before relying on income assumptions.

What does GERN stock do?

Commercial-stage biopharmaceutical company focused on telomerase inhibitor imetelstat (Rytelo) for hematologic myeloid malignancies including myelodysplastic syndromes (MDS) and myelofibrosis.

What is GERN stock's price target?

This cached page does not contain a precise model fair value for GERN.

The TradeMates model verdict for GERN is AVOID with an investment score of 39/100. Treat this as a model signal to review, not a personal buy recommendation.

Is GERN a good dividend stock?

GERN is not presented as a dividend idea on this cached TradeMates page because no positive dividend yield is available in the cached data.

GERN (GERN) Stock Analysis

Q: Is GERN stock a good investment?

The cached TradeMates AI model rates GERN as AVOID with an investment score of 39/100. The AI model evaluates Geron as an AVOID due to high leverage, ongoing cash burn of -$111.04M, and historical share dilution, which outweigh strong top-line revenue growth of $183.88M in FY2025. This is algorithmic model output, not personal investment advice.

Verdict: AVOID

Imetelstat commercial ramp drives rapid top-line growth, but heavy debt and persistent cash burn keep dilution risk acute.

Investment score: 39/100

The AI model evaluates Geron as an AVOID due to high leverage, ongoing cash burn of -$111.04M, and historical share dilution, which outweigh strong top-line revenue growth of $183.88M in FY2025.

View the full interactive analysis